Willow vs TMates: Oral GLP-1 with tracking vs $199/month care

Willow vs TMates compares two telehealth weight management approaches: Willow emphasizes oral GLP-1 plus structured progress tracking and follow-up, starting at 299, while TMates focuses on compounded semaglutide at a flat $199/month with 24/7 U.S. doctor access. Early verdict: choose Willow if you want a tracking-first, structured support model; choose TMates if you want flat-rate compounded semaglutide with continuous physician availability.

Explore Willow’s tracking-first program

How Willow and TMates differ at a glance

This comparison focuses on the most distinctive differences supported by the sources: delivery format and emphasis, pricing model and dose pricing, clinical access and availability, medication type and regulatory notes, and follow-up and tracking tools. Every claim below uses only the supplied evidence and qualifiers.

1. Delivery model and program emphasis

Willow is described as a telehealth-first weight management program that positions its oral GLP-1 offering as a structured weight management journey with progress tracking and follow-up support. TMates offers a straightforward GLP-1 experience delivering compounded semaglutide via a personalized, doctor-supervised model and virtual check-ins.

2. Pricing model and billing details

Willow’s captured evidence lists a starting price of 299 and a note of higher monthly entry pricing for some plans. TMates advertises a flat $199/month at every dose with no step-up fees, and captured landing-page details show monthly and multi-month package rates in several examples.

3. Clinical access and availability

Willow lists a licensed telehealth team and follow-up consultations; its treatment is available only when a licensed clinician determines it is medically appropriate. TMates highlights 24/7 access to U.S.-based doctors, licensed coverage in all 50 states, and virtual check-in appointments for ongoing medical oversight.

4. Medication type and regulatory notes

Willow positions an oral GLP-1 program; its evidence includes the regulatory caution that compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. TMates provides clinically dosed compounded semaglutide formulated in U.S.-based facilities and includes the same regulatory note that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.

5. Tracking, follow-up, and program focus

Willow emphasizes progress tracking tools and a structured support model intended to convert GLP-1 efficacy into longer-term changes, marketed to users who want structured digital follow-up. TMates emphasizes physician availability and virtual check-ins, with an operational focus on a flat-rate model and clinically dosed compounded semaglutide.

Comparison table: Willow vs TMates

Criteria	Willow	TMates
Primary offering	Oral GLP-1 with progress tracking	Compounded semaglutide (once-weekly injection)
Starting price	Starting at 299	$199/month flat
Price model	Higher monthly entry pricing for some plans noted	Flat $199/month at every dose, no step-up fees
Clinical access	Licensed telehealth team; follow-up consultations; treatment subject to clinician review	24/7 U.S. doctor access; licensed coverage in all 50 states; virtual check-ins
Medication type	Oral GLP-1; compounded medications, when offered, are not FDA-approved	Clinically dosed compounded semaglutide; compounded medications not FDA-approved
Program focus	Structured weight management journey, progress tracking tools	Flat-rate, physician-supervised semaglutide with free shipping

Clinical oversight and medication sourcing compared

Both providers operate with licensed clinician oversight, but the captured evidence highlights different clinician models. Willow frames its care around a licensed telehealth team with follow-up consultations and a workflow that emphasizes behavioral support and tracking. TMates emphasizes continuous 24/7 access to U.S.-based doctors across all 50 states and notes medications formulated in U.S.-based facilities. For users prioritizing ongoing direct physician availability, TMates explicitly advertises 24/7 doctor access; for users prioritizing structured digital follow-up tools the source describes Willow as best for those needs.

See TMates’ flat $199/month plan

Pricing and program predictability

If predictable per-dose pricing is a priority, TMates’ documented flat $199/month at every dose with no step-up fees is the clearly stated model. Willow’s captured evidence lists a starting price of 299 and notes higher monthly entry pricing for some plans, but does not provide an equivalent flat-rate promise in the captured content.

Compare Willow pricing and plans

Regulatory and medication notes

Both sources include the regulatory qualifier that compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness or quality when compounded products are part of the offering. TMates specifies its semaglutide is compounded and formulated in U.S.-based facilities; Willow’s note cautions that compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.

Final comparison and short conclusion

Willow vs TMates boils down to whether you value structured progress tracking and a program framing weight management as a behavioral journey with follow-up (Willow, starting at 299) or a flat-rate, clinically dosed compounded semaglutide program with 24/7 U.S. doctor access and free shipping at $199/month (TMates). Both include licensed clinician oversight and regulatory cautions about compounded medications where applicable.

Start TMates’ program details

Choose one if…

Choose Willow if you want a telehealth-first oral GLP-1 program built around progress tracking tools and structured digital follow-up and are comfortable with a starting price of 299 and clinician-determined treatment availability.

Choose TMates if you want compounded semaglutide at a flat $199/month with 24/7 access to U.S.-based doctors, licensed coverage in all 50 states, and free shipping where available. Both providers note that compounded medications are not FDA-approved when offered as compounded products.